康方生物回应!依沃西到底打没打败K药?

健识局
Yesterday

才刚刚和百济神州的PD-1替雷利珠打完擂台,依沃西单抗又出了“封神”数据:4月25日,康方生物的PD-1/VEGF双抗依沃西单抗注射液新适应症获批。获批正是基于投资者都关注的头对头K药的“AK112-303”临床数据:在PFS、OS方面,依沃西单抗都取得了显著阳性结果。没想到,市场并没有像上次一样热情追捧,反而让康方生物陷入了一场舆论风暴。去年9月“头对头”试验的后续数据公布,首次披露了总生存期(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10